Introduction {#S1}
============

A key protein in Gram-positive bacteria is DivIVA which is implicated in cell division and other functions ([@B13]; [@B6]; [@B25]; [@B60]; [@B63]; [@B10]; [@B31]). DivIVA self-interacts, oligomerizes and associates with a functionally different array of proteins in different Gram-positive bacteria ([@B31]). In *Bacillus subtilis* (Bs), DivIVA~Bs~ functions as a mid-cell determinant by attracting the MinC/MinD protein complex to the cell poles, thereby preventing cell division at the polar region ([@B13]; [@B23]; [@B47]; [@B24]; [@B39]; [@B32]). DivIVA~Bs~ also associates with the DNA binding protein RacA, which acts as a bridge between the *oriC* region and the cell poles, anchoring the chromosome at the poles during sporulation ([@B6]). In addition, DivIVA~Bs~ interacts with Spo0J, participating in chromosome segregation during sporulation ([@B6]; [@B74]; [@B59]); with ComN which is involved in competence development ([@B22]); and, with Maf, a regulator of cell shape and division ([@B12]). The interaction between Maf and DivIVA~Bs~ arrests cell division in competent cells ([@B10]). DivIVA of *Corynebacterium glutamicum* interacts with RodA and ParB ([@B21]; [@B69]), which binds the origin of replication with ParA, resulting in chromosomal segregation ([@B49]). DivIVA is involved in apical growth and control of cell polarity in *Streptomyces coelicolor* ([@B27]), by interacting with ParB to co-ordinate chromosomal segregation ([@B20]). DivIVA in *Streptococcus pneumoniae* interacts with several proteins implicated in divisome formation, including FtsZ, FtsA, ZapA, FtsK and FtsI, FtsB, FtsQ and FtsW ([@B26]). These studies highlight the diverse functionality of DivIVA in Gram-positive organisms. There is no information regarding DivIVA-associating proteins in *Enterococcus faecalis* (Ef).

*Enterococcus faecalis*, an opportunistic, commensal, Gram-positive, ovococcal pathogen is recognized for its resistance to multiple antibiotics and for causing hospital-acquired infections ([@B54]; [@B16]; [@B34], [@B35]; [@B70]). Enterococcal infections are potentially fatal, causing neonatal and wound infections, endocarditis, meningitis, and urinary tract infections ([@B34], [@B35]; [@B73]). Due to its ability to form biofilms, catheter-related urinary tract infections with *E. faecalis* are difficult to treat ([@B51]). To formulate new therapeutic agents and targets for resisting antibiotic resistant *E. faecalis* infections, a greater understanding of enterococcal biology, physiology and genetics is required.

*Enterococcus faecali*s contains DivIVA ([@B63]). This research describes a novel DivIVA-interacting protein, EF1025, which was annotated as a hypothetical protein in *E. faecalis* strain V583 ([@B58]). EF1025, which is conserved in most Gram-positive bacteria, contains a DNA binding domain at its N-terminus and two highly conserved Cystathionine β-Synthase (CBS) domains at the central and C-terminal regions. Bacterial Two-Hybrid (B2H), Glutathione S-Transferase (GST) pull-down, and Co-immunoprecipitation (Co-IP) assays were used to demonstrate interaction between EF1025 and DivIVA~Ef~. EF1025 self-interacts and forms a decamer. It was not possible to obtain viable cells after the deletion or insertional inactivation of *EF1025* without *in trans* expression of the gene. These rescued cells grew more slowly than wild type *E. faecalis*. Scanning electron microscopy (SEM) and atomic force microscopy (AFM) revealed cell elongation and aberrant cell shape in rescued cells. Cell elongation was also observed in SEM images when *EF1025* was overexpressed in *E. faecalis* cells. Using an *E. coli* model, overexpression of *EF1025* in *E. coli* PB103 resulted in filamentation. Immunofluorescence microscopy showed that EF1025 localized comparably to DivIVA~Ef~ localization during the later stages of cell division.

Materials and Methods {#S2}
=====================

Strains, Plasmids and Growth Conditions {#S2.SS1}
---------------------------------------

Strains and plasmids used in this study are listed in [Supplementary Tables S1, S2](#SM2){ref-type="supplementary-material"}. *E. coli* XL1-Blue or DH5α were used as hosts for cloning. *E. coli* C41 (DE3) was used to overexpress cloned proteins, *E. coli* PB103 ([@B17]) for heterologous overexpression of *E. faecalis* proteins, and *E. coli* R721 ([@B18], [@B19]) was used for the bacterial-two hybrid evaluations. *E. coli* strains were grown at 37°C in Luria-Bertani (LB) medium (Difco, Detroit, MI, United States) and antibiotics were included in the following concentrations as required: ampicillin (Amp) 100 μg/mL, kanamycin (Kan) 50 μg/mL and erythromycin (Ery) 125 μg/mL. *E. faecalis* JH2-2 ([@B37]), the parental strain, was used for the preparation of genomic DNA. *E. faecalis* was cultured at 37°C without aeration in Brain Heart Infusion (BHI) broth (Difco, Detroit, MI, United States) and supplemented with appropriate antibiotics if required ([@B63]; [@B65]). *Saccharomyces cerevisiae* SFY526, used in yeast two-hybrid (Y2H) assays (Clontech Laboratories, Inc., Mountain View, CA, United States), was grown at 30°C for 2--4 days on yeast extract-peptone-dextrose-adenine medium (YPDA) or on appropriate synthetic dropout media (Yeast Protocols Handbook, Clontech).

Bioinformatic Analysis {#S2.SS2}
----------------------

DNA sequences interacting with DivIVA~Ef~, identified after screening Y2H libraries of *E. faecalis* JH2-2 ([Supplementary Methods](#SM1){ref-type="supplementary-material"}) were blasted against the *E. faecalis* V583 genome ([@B58]) using NCBI BLAST^[1](#footnote1){ref-type="fn"}^. A putative open reading frame, named *EF1025* (GenBank accession number [NC_004668](NC_004668)), was identified from the *E. faecalis* V583 genome. The upstream sequence of *EF1025* (∼ 480 bp) was analyzed for promoter prediction^[2](#footnote2){ref-type="fn"}^ and the deduced amino acid sequence of EF1025 was ascertained using ProtParam^[3](#footnote3){ref-type="fn"}^. Homologs of EF1025 were identified using BLASTp^[4](#footnote4){ref-type="fn"}^ against the non-redundant protein sequences database. EF1025 was also analyzed by PROSITE ([@B71])^[5](#footnote5){ref-type="fn"}^ to identify functional domains. Transmembrane motifs in EF1025 were predicted using TMbase^[6](#footnote6){ref-type="fn"}^ and potential coiled-coil structures were predicted using COILS^[7](#footnote7){ref-type="fn"}^.

EF1025-DivIVA~Ef~ Interactions in the Bacterial Two-Hybrid Assays (B2H) {#S2.SS3}
-----------------------------------------------------------------------

The B2H system of [@B18], [@B19] was used to investigate interactions between DivIVA~Ef~ and EF1025 and its various domains. This particular assay involves a hybrid repressor which recognizes a chimeric operator. Potential interacting proteins are cloned at the two chimeric regions at the C-terminus of the hybrid repressor. The dimerization of the heterologous proteins permits reconstitution of the hybrid repressor which recognizes the chimeric operator and downregulates the activity of the downstream reporter gene, *lacZ* ([@B18]). Modified B2H vectors pcI434-L and pcIp22-L, containing a linker with multiple endonuclease restriction sites were used in B2H assays ([Supplementary Table S2A](#SM2){ref-type="supplementary-material"}) ([@B76]). *EF1025*, *EF1025-c* (encoding AA80-209 of EF1025) and *divIVA*~Ef~ were PCR-amplified from the *E. faecalis* JH2-2 using primers EF1025-F/R, EF1025C-F/R and CBdivIVA-F/R, respectively ([Supplementary Table S3A](#SM2){ref-type="supplementary-material"}) and cloned into the modified B2H vectors, resulting in plasmids pdivIVA22, pdivIVA434, pEF1025434, p22CBS1CBS2 and p434CBS1CBS2, respectively ([Supplementary Table S2A](#SM2){ref-type="supplementary-material"}). These plasmids were transformed into *E. coli* R721 alone or in combination ([@B18], [@B19]; [@B29]). Freshly transformed single colonies were grown overnight in 4 mL LB medium supplemented with Amp 50 μg/mL and Kan 30 μg/mL. Cells were diluted 1:100 using fresh LB medium containing the same antibiotics and were incubated for ∼1 h at 37°C, followed by the addition of 0.1 mM isopropyl β-[D]{.smallcaps}-1-thiogalactopyranoside (IPTG). Cells were further incubated to mid-log phase (OD600 ∼0.5) at 37°C, harvested, and tested for β-galactosidase activity, as previously described ([@B18]). Each experiment was performed in triplicate and the average percentage β-galactosidase activity was calculated.

GST Pull-Down Assays {#S2.SS4}
--------------------

To create a GST-DivIVA~Ef~ fusion, *divIVA*~Ef~ was PCR-amplified from genomic DNA from *E. faecalis* JH2-2 (see [Supplementary Methods](#SM1){ref-type="supplementary-material"}) using primers IVA-5/IVA-11 ([Supplementary Table S3B](#SM2){ref-type="supplementary-material"}) ([@B63]). The amplicon was cloned into pGEX-2T, generating plasmid pGST-Div ([Supplementary Table S2B](#SM2){ref-type="supplementary-material"}). *EF1025* was PCR-amplified from *E. faecalis* JH2-2 DNA using primers EF1025F-F/R ([Supplementary Table S3B](#SM2){ref-type="supplementary-material"}) and cloned into pET30a(+), resulting in plasmid pETEF1025 ([Supplementary Table S2B](#SM2){ref-type="supplementary-material"}). The two CBS domains, i.e. CBS1 and CBS2, of EF1025 were PCR-amplified from *E. faecalis* JH2-2 DNA using primers EF1025-CF/R and cloned into pET30a(+), resulting in plasmid pETEF1025CBS12 ([Supplementary Tables S2B, S3B](#SM2){ref-type="supplementary-material"}).

GST-DivIVA~Ef~, 6 × His-EF1025, or 6 × His-EF1025CBS12 fusions were overexpressed in *E. coli* C41 (DE3) ([@B63]). The GST-DivIVA~Ef~ fusion protein was purified using GST affinity beads (GST-Bind Kit, Novagen, United States). 6 × His-EF1025 or 6 × His-EF1025CBS12 were purified from 200 mL log-phase growth of *E. coli* C41 by sonication in 5 mL interaction buffer (IB, 20 mM Tris/HCl pH 7.5, 10% glycerol, 50 mM KCl, 0.5 mM EDTA, 1% Triton X100, 1 mM DTT). The cell lysate was centrifuged and the supernatant (50 μL) was incubated with 20 μL GST-DivIVA~Ef~ bound beads, pre-equilibrated with IB buffer, at 4°C for 2 h. Beads were washed with cold IB buffer 3× and the retained protein was eluted using a 40 μL 1 × SDS loading buffer and heating at 95°C for 10 min. Eluted protein was separated by SDS-PAGE, followed by Western blot analysis using anti-6 × His monoclonal antibody (Biorad, United States). The same protocol was used to study the DivIVA~Ef~ and EF1025-CBS12 interaction. Purified GST protein was used as a control and was produced in *E. coli* C41 (DE3) from plasmid pGEX2T.

Production of Anti-EF1025 Polyclonal Antibody {#S2.SS5}
---------------------------------------------

6 × His-EF1025 was overexpressed in *E. coli* C41DE3 from plasmid pETEF1025 ([Supplementary Table S2B](#SM2){ref-type="supplementary-material"}) and was purified as described previously ([@B63]). Female New Zealand White rabbits were injected with ∼30 μg/mL purified 6 × His-EF1025 in Freund's adjuvant (Sigma; v/v = 1:1) at the Animal Core Facility of the Vaccine and Infectious Diseases Organization (University of Saskatchewan) with a booster dose on day 21 after the initial injection. Polyclonal IgG antibody was purified by affinity purification of antiserum using Protein-A sepharose beads (Pharmacia Bioscience; [@B63]). Antibody specificity was tested by western blotting assay using an *E. faecalis* JH2-2 whole cell protein extract which was prepared by sonicating 50 mL of cell culture and resuspending the cells in 2.5 mL of Tris buffer ([Supplementary Figure S1](#SM3){ref-type="supplementary-material"}). Previously prepared anti-DivIVA~Ef~ ([@B63]) was used as a positive control.

Co-immunoprecipitation (Co-IP) {#S2.SS6}
------------------------------

An overnight culture of *E. faecalis* JH2-2 was diluted 1:100 in BHI broth and incubated for 16--20 h at 37°C without aeration. Two hundred mL were centrifuged at 10,000 rpm for 10 min and the pellet was re-suspended in 5 mL Co-IP buffer (25 mM HEPES pH7.9, 100 mM NaCl, 5% glycerol, 0.5 mM EDTA, 0.1% Triton X100, 1 mM DTT and 0.5 mM PMSF). The suspension was sonicated, on ice, 3×, for 30 s each, with an interval of 20 s. The cell lysate was centrifuged under the same conditions (above) and the supernatant was collected for Co-IP assays.

Protein-A Sepharose beads (Pharmacia Inc., Canada) were cross-linked with 20 μg of either anti-DivIVA~Ef~ or anti-EF1025 polyclonal antibody in 200 μL PBS as follows: antibody was incubated with 50 μL Protein-A Sepharose beads at room temperature (RT) for 1 h. Beads were washed with PBS once and then washed twice with 0.2 M sodium borate (pH 9.0). Dimethylpimelimdate (Sigma) was added to the beads to a final concentration of 20 mM and incubated for 30 min at RT to allow cross-linking. The reaction was stopped by adding 0.2 M ethanolamine (final concentration 20 mM) pH8.0 (Sigma) and incubating at RT for 2 h. Beads were then washed with PBS and stored at 4°C for later use. Prior to Co-IP, 20 μL antibody-bound beads were incubated with 10 mg/mL BSA overnight at 4°C to block non-specific binding sites. Beads were then equilibrated with Co-IP buffer and subsequently incubated with 200 μL of *E. faecalis* JH2-2 cell extract for 2 h at 4°C. After removing the supernatant, beads were washed with Co-IP buffer 3 × for 10 min each. Proteins retained on the beads were eluted in 80 μL 1 × SDS loading buffer, separated on 12% SDS-PAGE, and transferred onto a nitrocellulose membrane for Western blot assay. Blots were probed with either anti-DivIVA~Ef~ or anti-EF1025 polyclonal antibody. Beads alone or beads cross-linked with anti-MinC~Ng~ polyclonal antibody ([@B64]) were used as negative controls.

EF1025 Self-Interaction {#S2.SS7}
-----------------------

To determine whether EF1025 self-interacts, and to map the sites responsible for self-interaction, the predicted functional domains of EF1025 were cloned, in different combinations, into Y2H vectors as follows: EF1025CBS12 (AA80-204) carrying CBS1 and CBS2 domains, NCBS1-EF1025 (AA6-137) containing the N-terminus HTH domain and CBS1 domain, CBS2-EF1025 (AA144-204) containing the CBS2 domain, and N-EF1025 (AA6-50) containing the N-terminus HTH domain. *E. faecalis* JH2-2 DNA was used as a template for PCR amplification of these fragments. Primers for the amplification of various fragments are described in [Supplementary Table S3C](#SM2){ref-type="supplementary-material"}. These amplicons were cloned into the vectors pGAD424 and pGBT9 resulting in plasmids pGADEF1025CBS12, pGBDEF1025CBS12, pGADEF1025NCBS1, pGBDEF1025NCBS1, pGADEF1025C BS2, pGBDEF1025CBS2, pGADEF1025-N, and pGBDEF1025-N, respectively ([Supplementary Table S2C](#SM2){ref-type="supplementary-material"}). Each plasmid construct was co-transformed with a plasmid expressing full-length EF1025 (e.g. pGADEF1025 or pGBDEF1025) into *S. cerevisiae* SFY526. Transformation efficiencies were calculated by plating 50 μL of diluted transformants on separate plates followed by counting the number of colonies produced. Transformants were selected on complete synthetic medium lacking leucine and tryptophan (SD-leu-trp) (Clontech). Transformation efficiencies were calculated by plating 50 μL of diluted transformants on separate plates followed by counting the number of colonies produced. After 3--4 days of incubation at 30°C, using a colony lift assay (Clontech), cells were screened for blue color development in the presence of 5-Bromo-4-chloro-3-indolyl-β-[D]{.smallcaps}-galactopyranoside (X-Gal, Sigma-Aldrich; St. Louis, MS) to study the self-interaction ability of EF1025. Positive clones were further subcultured in SD-leu-trp broth and a spectrophotometric assay for β-galactosidase activity, using the substrate *o*-nitrophenyl-β-[D]{.smallcaps}-galactopyranoside was performed ([@B63]).

SEC-MALS, the combination of Size Exclusion Chromatography with Multi-Angle Light Scattering analysis (Wyatt Technology, United States), was used to determine the oligomerization state of EF1025. Using His-bind resin (Novagen, Canada), 1mg of purified 6 × His-EF1025 was loaded onto a Superdex 200 column (Biorad) equilibrated with a buffer comprising 50 mM Tris base, 400 mM NaCl, pH 7.4. A single peak, corresponding to EF1025 eluted by SEC, was detected by the MALS detector to estimate molar mass.

Overexpression of *EF1025* in *E. faecalis* JH2-2 {#S2.SS8}
-------------------------------------------------

To overexpress *EF1025* in *E. faecalis* JH2-2, *EF1025* was cloned into pMSP3545 ([Supplementary Table S2](#SM2){ref-type="supplementary-material"}). pMSP3545 was first modified by introducing an Amp-encoding gene that was PCR amplified from pcDNA3.1(+) using primer pairs AmpF/R ([Supplementary Table S3D](#SM2){ref-type="supplementary-material"}), into pMSP3545 creating pMSP3545A ([Supplementary Table S2D](#SM2){ref-type="supplementary-material"}). Linkers LinkA/B ([Supplementary Table S3D](#SM2){ref-type="supplementary-material"}), which contained restriction sites *Bam*HI and *Nco*I, were ligated to the Amp gene amplicon prior to ligation in pMSP3545. pMSP3545A was electroporated into electrocompetent *E. faecalis* JH2-2 cells using previously described methods ([@B63]) and colonies were selected on BHI supplemented with Ery (125 μg/mL), creating *E. faecalis* MK0. *E. faecalis* JH2-2 and *E. faecalis* MK0 served as controls for all electroporation experiments. *EF1025* and 80 bp upstream, which included the predicted promoter sequence, was PCR amplified using primers EF1025npF/R, and the amplicon was digested with *Nco*I and *Xba*I, purified and subcloned into pMSP3545A, digested with the same enzymes, creating pMSPEF1025A ([Supplementary Table S2D](#SM2){ref-type="supplementary-material"}). pMSPEF1025A was transformed into *E. coli* DH5α and transformants were selected for Amp resistance. Clones were confirmed for the presence of EF1025 using restriction digestion and PCR amplification with primers EF1025npF/R. pMSPEF1025A was electroporated into electrocompetent *E. faecalis* JH2-2 cells creating *E. faecalis* MK23 ([Supplementary Table S1](#SM2){ref-type="supplementary-material"}) using previous methods ([@B63]). To ascertain whether EF1025 was expressed from its native promoter in pMSPEF1025A, pMSPEF1025-flag was created by fusing a flag-tag encoding sequence which was PCR amplified from pcDNA3.1(+) using primers flagF/R ([Supplementary Table S3D](#SM2){ref-type="supplementary-material"}). The amplicon was ligated in pMSPEF1025A downstream of *EF1025* and electroporated into electrocompetent *E. faecalis* JH2-2 cells to create *E. faecalis* MK24 ([Supplementary Table S1](#SM2){ref-type="supplementary-material"}). EF1025 expression from pMSPEF1025-flag in *E. faecalis* MK24 was evaluated using an anti-flag monoclonal antibody (GenScript, United States) by Western blot analysis. Whole cell extracts of both *E. faecalis* JH2-2, *E. faecalis* MK23 and *E. faecalis* MK24 were prepared for these blots. In a separate Western blot, anti-EF1025 antibody was used to compare EF1025 expression levels in the same strains.

Complementation *of EF1025* Deletions and Insertional Mutants in *E. faecalis JH2-2* {#S2.SS9}
------------------------------------------------------------------------------------

Clones of insertionally inactivated or deleted EF1025 in *E. faecalis* JH2-2 could not be recovered unless EF1025 was expressed *in trans*. Therefore, *E. faecalis* JH2-2 was co-transformed both with plasmids expressing EF1025 (i.e. either pMSPEF1025-pro or pMSPEF1025A) and plasmid constructs designed to insertionally inactive (i.e. p3ERMEF1025::Kan) or delete (i.e. p3ERMΔEF1025::Cat) EF1025.

To create p3ERMEF1025::Kan, first the N-terminal sequence of *EF1025* (AA1-55) was PCR-amplified from *E. faecalis* JH2-2 using primers CBSDPF/CBS55R-Hind ([Supplementary Table S3D](#SM2){ref-type="supplementary-material"}). The amplicon was digested and ligated to predigested pUC18, resulting in pUCEF1025-N ([Supplementary Table S2D](#SM2){ref-type="supplementary-material"}). Then, a kanamycin cassette (*Kan*^R^) was PCR-amplified from pTCV-lac ([Supplementary Table S2D](#SM2){ref-type="supplementary-material"}; [@B61]) with primers KanF/R ([Supplementary Table S3D](#SM2){ref-type="supplementary-material"}), and the amplicon was inserted into pUCEF1025-N at its *Hin*dIII/*Sma*I sites, producing plasmid pUCEF1025-N-Kan ([Supplementary Table S2D](#SM2){ref-type="supplementary-material"}). The C-terminal sequence of EF1025 (AA56-209) was PCR-amplified from *E. faecalis* JH2-2 with primers CBS55F-*Sma*I/EF1025-R-*Bam*HI ([Supplementary Table S3D](#SM2){ref-type="supplementary-material"}) and the amplicon was inserted into pUCEF1025-N-Kan creating the plasmid pUCEF1025::Kan ([Supplementary Table S2D](#SM2){ref-type="supplementary-material"}). Finally, pUCEF1025::Kan was digested with *Eco*RI and *Bam*HI, yielding a fragment containing *EF1025-N, Kan^R^* and *EF1025-C.* This fragment was ligated into p3ERM-H, creating the suicide vector p3ERMEF1025::Kan ([Supplementary Table S2D](#SM2){ref-type="supplementary-material"}; [@B63]). This plasmid was electroporated into *E. faecalis* JH2-2 ([@B63]) with selection attempted using BHI agar containing Kan 500 μg/mL and incubation at 37°C for 2--3 days. Transformants were never obtained after multiple attempts, so p3ERMEF1025::Kan was co-electroporated with the shuttle plasmid pMSPEF1025-Pro that expresses wild type *EF1025 in trans* from its native promoter ([Supplementary Table S2D](#SM2){ref-type="supplementary-material"}) into *E. faecalis* JH2-2 to create *E. faecalis* MJ26 ([Supplementary Table S3C](#SM2){ref-type="supplementary-material"}; [@B63]). Transformants were selected on BHI supplemented with Ery (125 μg/mL) and Kan (500 μg/mL). For each electroporation experiment, we used *E. faecalis* JH2-2 and MK0 as controls for growth on BHI supplemented with erythromycin. *E. faecalis* JH2-2 failed to grow in the presence of erythromycin while *E. faecalis* MK0 grew well. To confirm that transformants contained both an insertionally inactivated chromosomal *EF1025* as well as *EF1025* expressed *in trans* from pMSPEF1025-pro in *E. faecalis* MJ26, primers mutF/Kan-R, KanF/KanR, EF1025-Pro/KanR and KanF/CBSDPR were used to amplify chromosomal and plasmid fragments, followed by DNA sequencing of all amplified fragments for confirmation of the insertion ([Supplementary Table S3D](#SM2){ref-type="supplementary-material"}).

To ensure that phenotypes observed in *E. faecalis* MJ26 were not caused by polar effects of the insertional mutagenesis of EF1025 on the downstream gene EF1026, qPCR was performed to study the expression of both genes ([Supplementary Methods](#SM1){ref-type="supplementary-material"}).

A second strategy to inactivate *EF1025* in *E. faecalis* JH2-2 involved the non-polar deletion of chromosomal *EF1025* ([@B44]) by introduction of the suicide plasmid pERMΔEF1025::Cat. Partial overlapping flanking primers ppdkF/R-*Bam*HI ([Supplementary Table S3D](#SM2){ref-type="supplementary-material"}) were used to amplify 500 bp upstream (includes the native promoter of *EF1025*) of the start codon of *EF1025* and 500 bp downstream of the stop codon of *EF1025* using primers 1026F/R-*Eco*RI ([Supplementary Table S3D](#SM2){ref-type="supplementary-material"}) of *E. faecalis* JH2-2 DNA. A chloramphenicol cassette was amplified from pLemo (NEB) using primers CatF/R ([Supplementary Table S3D](#SM2){ref-type="supplementary-material"}). The three fragments were combined by overlap PCR amplification ([@B36]), creating a fragment that contained the chloramphenicol cassette flanked by the 500 bp upstream fragment and 500 bp downstream fragment. The resultant fragment was purified, digested and ligated into p3ERM-H, creating the suicide vector p3ERMΔEF1025::Cat ([Supplementary Table S2D](#SM2){ref-type="supplementary-material"}). As no transformants were recovered after electroporation of p3ERMΔEF1025::Cat into *E. faecalis* JH2-2, this plasmid along with pMSPEF1025A ([Supplementary Table S2D](#SM2){ref-type="supplementary-material"}) were co-electroporated into *E. faecalis* JH2-2 ([@B68]) creating *E. faecalis* MK12. Transformants were selected on BHI agar plates containing Chl 5 μg/mL and Ery 125 μg/mL, incubated at 37°C for 2--3 days. The deletion of *EF1025* in *E. faecalis* MK12 was confirmed by PCR-amplification using primers ppdkF/EF26b-R, mutF/EF26b-R, ppdkF/EF1025npR, EF1025npF/1026R, CatF/1026R and CatF/R ([Supplementary Tables S3C,D](#SM2){ref-type="supplementary-material"}) followed by DNA sequencing of these amplified fragments (data not shown).

*Enterococcus faecalis* JH2-2 did not grow at this concentration of chloramphenicol. As a positive control, p3ERMΔEF1025::Cat was electroporated into *E. coli* DH5α and transformants were selected on LB agar plates containing Chl 33 μg/mL after incubation for 24 h at 37°C.

Microscopy {#S2.SS10}
----------

A SU8010 Cold Field Emission Ultra-High-Resolution scanning electron microscope (WCVM, University of Saskatchewan, Saskatoon, SK, Canada) was used to image *E. faecalis* strains JH2-2, MK0, MK12, MJ26, MK23, MK24 ([Supplementary Table S1](#SM2){ref-type="supplementary-material"}). Strains were cultured in BHI medium with or without appropriate antibiotics, without agitation, at 37°C, either overnight (∼20 h) or to stationary phase. Cells were fixed on poly-L-lysine coverslips, dehydrated in ethanol, critical point dried, sputter coated with gold and imaged ([@B64]). Length measurements were performed across the poles of the diplococcal bacteria and the percentage of elongated cells was calculated by measuring the lengths of 110--250 cells.

A Hitachi HT7700 High Contrast High-Resolution Digital Transmission Electron Microscope (WCVM, University of Saskatchewan, Saskatoon, Saskatchewan) was used to image *E. faecalis* strains JH2-2 and MJ26 prepared as previously described ([@B63]).

Immuno-Fluorescence Microscopy of *E. faecalis* JH2-2 {#S2.SS11}
-----------------------------------------------------

To visualize DivIVA~Ef~ and EF1025 localization, *E. faecalis* JH2-2 cells in exponential phase were collected and fixed using a procedure modified from [@B32]. One mL of cell culture was harvested and the resuspended pellet was fixed with 1 ml fixation buffer (2.5% paraformaldehyde, 0.03% glutaraldehyde in 30 mM sodium phosphate buffer pH 7.5) for 30 min, at RT, then for 2 h at 4°C. Cells were washed 3× with 1 × PBS and resuspended in 200 μL GTE (50 mM glucose, 20 mM Tris-HCl pH 7.5, 10 mM EDTA) to which a freshly prepared lysozyme solution (2 mg/mL) was added. This volume was transferred to and fixed on poly-L-lysine coated coverslips. Cells attached to the coverslips were blocked with BSA-PBST (3% bovine serum albumin \[wt/vol\] and 0.2% Triton X-100 \[vol/vol\] in PBS) for 2 h at RT. Cells were then incubated with either anti-DivIVA~Ef~ (1:200) or anti-EF1025 (1:100) in BSA-PBST for 3 h at RT. After washing with PBST, cells were incubated with a fluorescence-labeled secondary antibody (1:500 dilutions in BSA-PBST, goat anti-rabbit Alexa Fluor 488, Invitrogen) for 45 min. Images were acquired using U-M655 and U-M665 filters and processed using *InVitro* 3 and ImagePro 6.0 software (Media Cybernetics). Each experiment was performed 4× using 2 independent cell cultures, and about 300 cells were counted for each immuno-staining. Cells were also stained with DAPI (Thermo Fisher, CA) and were mounted and observed under a 100X oil immersion objective using an Olympus BX61 microscope with standard filters. DAPI-stained cells were divided into five cell division stages. Stage 1 was defined as a single cell with a central condensed chromosome. Stage 2 cells contained a segregating chromosome as the cell started to divide. Stages 3 and 4 defined by the presence of two newly replicated cells with segregated chromosomes. As the cell completed one round of cell division, Stage 5 comprised of two daughter cells with condensed DNA in the center. *E. faecalis* MWMR16 cells, containing point mutations in the coiled coil region of DivIVA~Ef~, were used as negative control ([@B65]).

Results {#S3}
=======

Identification and *in silico* Analysis of a Novel DivIVA~Ef~ Interacting Protein in *E. faecalis* {#S3.SS1}
--------------------------------------------------------------------------------------------------

To identify DivIVA~Ef~ interacting proteins from *E. faecalis*, a Y2H system was used to screen an *E. faecalis* genomic DNA library using DivIVA~Ef~ as the bait protein (data not shown). Positive clones were sequenced and bioinformatic analysis indicated a sequence corresponding to the C-terminus of the hypothetical protein EF1025 (GenBank accession \# NP_814759) of the *E. faecalis* V583 genome; *EF1025* spans nucleotide positions 983760-984389 ([Figure 1A](#F1){ref-type="fig"}). *In silico* analysis of *EF1025* indicated that a ribosome binding site (GGAGG) is located at nucleotide position (nt) --6 to --10, and a putative promoter at position nt −36 to −87. *EF1025* has a transcriptional orientation ([Figure 1B](#F1){ref-type="fig"}) similar to the downstream gene *EF1026*, a hypothetical protein with a kinase phosphoprotein phosphatase (PPPase) domain. A predicated terminator sequence is located downstream of *EF1026*. The upstream gene, *EF1024*, is transcribed in the opposite orientation of *EF1025* and *EF1026* and encodes a putative pyruvate phosphate dikinase (PPDK) domain ([Figure 1B](#F1){ref-type="fig"}).

![**(A)** *EF1025* position in *E. faecalis* V583 genome. Transcriptional orientation of genes upstream (i.e. EF1024) and downstream (i.e. EF1026 and EF1027) to *EF1025* (i.e. EF1025). The direction of an arrow within the rectangle indicates the transcriptional orientation of the gene. The bent arrow indicates promoter region upstream of EF1025 and vertical line indicates terminator region. **(B)** EF1025 domain prediction. N, N-terminus; C, C-terminus; HTH, Helix-turn-helix domain; CBS, Cystathionine-β-Synthase domain. Space in between domains constitutes hinge regions.](fmicb-11-00083-g001){#F1}

EF1025 comprises 209 amino acids (AA), with a molecular weight of ∼23 kDa and a theoretical isoelectric point of 6.75. Domain prediction studies ([Figure 1B](#F1){ref-type="fig"}) showed that EF1025 contains an N-terminal Helix-turn-Helix (HTH) DNA binding domain (AA 6-50), and two CBS domains (i.e. CBS1, AA 80-137 and CBS2, AA 144-204). The CBS1 domain is in the central region of EF1025 and CBS2 is located at the C-terminus. EF1025 does not contain any transmembrane motifs (suggesting that it is a cytosolic protein), nor does it contain coiled-coil regions.

The EF1025 protein sequence was used as a query in BLASTp against 10000 targeted sequences in the non-redundant (nr) protein sequences database (last accessed May 2019). EF1025 was identified as belonging to the CBS pair superfamily and is conserved predominantly in Gram-positive bacteria, primarily in Firmicutes. As with EF1025, Gram-positive homologs contain an N-terminal HTH domain and two CBS domains located centrally and at the C-terminal. In *B*. *subtilis*, the EF1025 homolog is named CcpN and is involved in the gluconeogenic pathway ([@B67]).

EF1025 Oligomerizes and Self-Interacts {#S3.SS2}
--------------------------------------

To determine whether EF1025 self-interacts, fragments comprising different combinations of domains of *EF1025* were cloned into Y2H vectors and initially tested for interactions using the colony lift assay (data not shown), followed by a quantitative assay for β-galactosidase activity. The quantitative assay indicated that EF1025 strongly self-interacts ([Figure 2](#F2){ref-type="fig"}). Furthermore, the EF1025CBS12, containing the CBS1 and CBS2 domains, strongly interacted with EF1025. Fragments containing the N-terminus HTH domain and the central CBS1 domain (i.e. EF1025NCBS1) and fragments EF1025CBS2 (contains CBS2 domain) and EF1025-N (i.e. N-terminus HTH domain) showed no interaction with EF1025.

![EF1025 self-interacts using its CBS1 and CBS2 domains. EF1025 self-interacts in the Y2H assay. Bars represent full-length and truncations of EF1025. Amino acid positions are indicated on the top. Open bars, predicted domains; closed bars, hinge regions; HTH, helix-turn-helix domain; CBS, cystathionine-β-synthase; Full-length EF1025 contains 209 amino acids (AA1-209); CBS12, EF1025 CBS1 and CBS2 domains together (AA80-204); NCBS1, N-terminus and CBS1 domain of EF1025 (AA1-131); CBS2, CBS2 domain of EF1025 (AA131-209); N, N-terminus of EF1025 (AA1-50). ND, not detectable. The experiment was conducted in triplicate. SD, standard deviation.](fmicb-11-00083-g002){#F2}

6×His-EF1025 was found to be a decamer, with an estimated molecular mass of 222 kDa, using a combination of Size Exclusion Chromatography (SEC) with Multi-Angle Light Scattering (MALS) analysis ([Supplementary Figure S2](#SM3){ref-type="supplementary-material"}). Reduced disulfide linkages, achieved by adding 1 mM Dithiothreitol, did not change the overall molecular weight of 6×His-EF1025.

EF1025 Interacts With DivIVA~Ef~ *in vitro* and *in vivo* {#S3.SS3}
---------------------------------------------------------

A B2H system was used to confirm preliminary Y2H results, showing the interaction of EF1025 with DivIVA~Ef~. In this assay, less than 50% residual β-galactosidase activity is indicative of a positive interaction ([@B18]; [@B76]). *E. coli* R721 cells showed a baseline residual β-galactosidase activity of 100%. *E. coli* R721 transformed, with one of pdivIVA22, pdivIVA434, pEF1025434, p434CBS1CBS2, or p22CBS1CBS2, showed residual β-galactosidase activities of 78, 82, 55, 66, and 77%, respectively, and served as negative controls. The positive control (*E. coli* R721 cells containing plasmids pdivIVA22 and pdivIVA434), which demonstrated the self-interaction of DivIVA~Ef~ ([@B63]), displayed 36% residual β-galactosidase activity. Our results indicate an interaction between DivIVA~Ef~ and EF1025 ([Figure 3](#F3){ref-type="fig"}; pdivIVA434 and p22EF1025 together) with a residual β-galactosidase activity of 21%. The two CBS domains together (i.e. p22CBS1CBS2 or p434CBS1CBS2) also interacted with DivIVA~Ef~ (pdivIVA434 or pdivIVA22) with 14% residual β-galactosidase activity.

![EF1025 interacts with DivIVA~Ef.~ in B2H assay. The β-galactosidase activity was expressed in percentage Miller Units (*y*-axis). The *x*-axis shows the combination of B2H plasmids used in the experiment. Average values were obtained from three independent assays in triplicates. Values of less than 50% indicate a positive interaction. The error bars represent 1 standard deviation.](fmicb-11-00083-g003){#F3}

The interaction between EF1025 and DivIVA~Ef~ was also ascertained using a GST-pull down assay. A Western blot using anti-EF1025 antibody revealed that GST-DivIVA~Ef~ was pulled down by 6×His-EF1025 ([Figure 4A](#F4){ref-type="fig"}, Lane 3) or 6×His-EF1025CBS12 ([Supplementary Figure S3](#SM3){ref-type="supplementary-material"}, Lane 3). GST did not interact with 6 × His-EF1025 ([Figure 4A](#F4){ref-type="fig"}, Lane 2) or 6×His- EF1025-C ([Supplementary Figure S3](#SM3){ref-type="supplementary-material"}, Lane 2).

![Interaction of EF1025 with DivIVA~Ef~. **(A)** GST pull-down assay. Shown is the Western blot probed with anti-6 × His (Bio-Rad, CA) monoclonal antibody to check the presence of EF1025. Lane 1: supernatant containing overexpressed EF1025 representing 10% input of EF1025; Lane 2: GST bound beads; Lane 3: GST-DivIVA~Ef~ bound beads; Lane 5: Protein ladder. **(B)** Co-immunoprecipitation assay of EF1025. EF1025 was co-precipitated with DivIVA~Ef~ using the anti-DivIVA~Ef~ antibody as bait. The blot was probed with the anti-EF1025 polyclonal antibody. Lane 1: *E. faecalis* extracts representing 10% input in Co-IP assays; Lane 2: anti-DivIVA~Ef~ antibody bound beads; Lane 3: beads alone; Lane 4: anti-MinC~Ng~ antibody bound beads. **(C)** Co-immunoprecipitation assay of DivIVA~Ef~. DivIVA~Ef~ with EF1025 using anti-EF1025 antibody as bait. The blot was probed with an anti-DivIVA~Ef~ polyclonal antibody. Lane 1: *E. faecalis* extracts representing 10% input in Co-IP assays; Lane 2: anti-EF1025 antibody bound beads; Lane 3: beads alone; Lane 4: anti-MinC~Ng~ antibody bound beads. --- indicates the absence of any protein.](fmicb-11-00083-g004){#F4}

The *in vitro* interaction between EF1025 and DivIVA~Ef~ was also determined using a Co-IP assay. EF1025 co-precipitated with DivIVA~Ef~ using anti-DivIVA~Ef~ antibody ([Figure 4B](#F4){ref-type="fig"}, Lane 2), and DivIVA~Ef~ co-precipitated with EF1025 with anti-EF1025 antibody ([Figure 4C](#F4){ref-type="fig"}, Lane 2). As a negative control, anti-MinC~Ng~ (MinC from *N. gonorrhoeae*) antiserum failed to precipitate EF1025 or DivIVA~Ef~ ([Figures 4B,C](#F4){ref-type="fig"} Lane 4).

*In trans* Complementation of Inactivated or Deleted *EF1025* {#S3.SS4}
-------------------------------------------------------------

Two strategies were used to inactivate or delete *EF1025* in *E. faecalis* JH2-2. First, we attempted to insert a *Kan*^R^ cassette at position nt151 (AA50 and [Supplementary Figure S4A](#SM3){ref-type="supplementary-material"}) of *EF1025* using p3ERMEF1025:Kan. No transformants were recovered after several attempts. The second strategy, in which an *EF1025* deletion mutant would be created by in frame replacement of *EF1025* (p3ERM EF1025:Cat) with a *Cat*^R^ cassette in *E. faecalis* JH2-2 also failed to produce transformant colonies. Expression of EF1025 was rescued by co-transformation with plasmid combinations p3ERMEF1025:Kan and pMSPEF1025-pro, and p3ERMΔEF1025:Cat and pMSPEF1025A. These rescue strategies were successful, creating transformant strains *E. faecalis* MJ26 and MK12, respectively ([Supplementary Figure S4B](#SM3){ref-type="supplementary-material"}). Taken together, the data suggest that *EF1025* may be an essential gene. *E. faecalis* MJ26 and MK12 grew more slowly than *E. faecalis* JH2-2 ([Supplementary Figure S5](#SM3){ref-type="supplementary-material"}).

The expression *EF1026* in *E. faecalis MJ26* was determined by RT-PCR in order to ascertain that the apparently lethal effects of the Kan^R^ insertion in *EF1025* was not due to polar effects on this gene. Amplified DNA fragments corresponding to the various regions of *EF1026* indicated that the gene was transcribed ([Supplementary Figure S6](#SM3){ref-type="supplementary-material"}). Expression levels (i.e. ΔC~T~ values) for *EF1026* in *E. faecalis* JH2-2 (i.e. 16.88 ± 0.13) and *E. faecalis* MJ26 (i.e. 16.79 ± 0.04) were equal.

The phenotypes of *E. faecalis* MJ26 and MK12 differed from wild type *E. faecalis* JH2-2. SEM of *E. faecalis* JH2-2 showed cells with symmetrical division at the mid-cell with characteristic ovococcal cell morphology ([Figures 5A](#F5){ref-type="fig"}, [6A](#F6){ref-type="fig"}). *E. faecalis* MJ26 and *E. faecalis* MK12 cells formed elongated cells with distorted cell shapes ([Figures 5B,C](#F5){ref-type="fig"}) which were aggregated, failed to segregate ([Figure 5B](#F5){ref-type="fig"}) and had multiple division sites within a single elongated cell ([Figure 5C](#F5){ref-type="fig"}). Compared to the length of the wild type *E. faecalis* JH2-2 cells (1.16 ± 0.14 μm, *n* = 141), 47% of *E. faecalis* MJ26 (1.63 ± 0.29 μm, *n* = 174) and 49% of *E. faecalis* MK12 (1.74 ± 0.27 μm, *n* = 127) cells were significantly (*p* \< 0.05) longer ([Figure 5D](#F5){ref-type="fig"}) when measured across the poles. The control *E. faecalis* MK0 (i.e. contains empty plasmid pMSP3545A) had a cell length (1.15 ± 0.18 μm, *n* = 165) identical (*p* \< 0.05) to *E. faecalis* JH2-2 ([Figure 5D](#F5){ref-type="fig"}). Transmission electron microscopy showed that 10% of *E. faecalis* MJ26 cells were aggregated (*n* = 273) with abnormal septation, resulting in daughter cells of different sizes and shapes ([Figures 6B--D](#F6){ref-type="fig"}). In addition, atomic force microscopy (AFM) ([Supplementary Methods](#SM1){ref-type="supplementary-material"}) showed larger aggregated cell clusters for *E. faecalis* MK12 as compared to *E. faecalis* JH2-2 ([Supplementary Figure S7](#SM3){ref-type="supplementary-material"}).

![Rescued *E. faecalis* cells (i.e. *E. faecalis* MJ26 and MK12) showed compromised cell division phenotypes. Scanning electron micrographs showing **(A)** Normal *E. faecalis* JH2-2 lancet-shaped cells; **(B)** aggregated *E. faecalis* MJ26 cells with impaired segregation; **(C)** *E. faecalis* MK12 cells showing impaired cell shape and multiple division sites. White arrow indicates aggregated cells that failed to segregate; red arrows indicate cells with distorted cell shape; yellow arrows indicate cells with formation of multiple division rings. Bar scale indicated at the bottom right corner of each image; **(D)** Comparison of cell lengths for *E. faecalis* strains: JH2-2 (*n* = 141), MK0 (*n* = 165, harboring pMSPEA), MK12 (*n* = 127) and MJ26 (*n* = 174). *E. faecalis* strains JH2-2 and MK0 served as control strains. "n" represents the number of cells counted for each sample; two-tail *p* value from *t*-test for each group set has been indicated in the graph. All data was analyzed by *t*-test and ANOVA analysis, where *p*-value was \< 0.05. The error bars represent 1 standard deviation.](fmicb-11-00083-g005){#F5}

![*Enterococcus faecalis* MJ26 cells showed impaired cell division. Transmission electron micrographs showing **(A)** wild-type *E. faecalis* JH2-2 lancet-shaped cells; **(B--D)** *E. faecalis* MJ26 cells with aggregated cells that failed to segregate and impaired septation leading to unequal daughter cells. Black arrows indicate aggregated cells that failed to segregate; red arrows indicate septa formation at random sites within the cells. Bar scale indicated at the bottom right corner of each image.](fmicb-11-00083-g006){#F6}

Overexpression of *EF1025* in *E. faecalis* and *E. coli* Induces Cell Elongation {#S3.SS5}
---------------------------------------------------------------------------------

*Enterococcus faecalis* MK23 was created in which *EF1025* is expressed from its native promoter both from the chromosome and from pMSPEF1025A. In order to ensure that *EF1025* could be expressed from its native promoter *in trans*, *E. faecalis* MK24 was constructed (contains pMSPEF1025-flag) and the protein detected in whole cell extract by Western blot using a monoclonal anti-flag antibody ([Supplementary Figure S8A](#SM3){ref-type="supplementary-material"}. Lane 3). Expression of EF1025-flag was not detected in *E. faecalis* JH2-2 or MK23 cell extracts ([Supplementary Figure S8A](#SM3){ref-type="supplementary-material"}, Lanes 1 and 2). This confirmed expression of an extrachromosomal copy of EF1025 in *E. faecalis* MK24 when electroporated with pMSPEF1025-flag. This shows that *E. faecalis* MK23 also carries enhanced expression levels of EF1025 due to the presence of an extrachromosomal copy of EF1025. When anti-EF1025 antibody was used to identify the expression levels of EF1025, overexpression of EF1025 in *E. faecalis* MK23 and *E. faecalis* MK24 was observed as determined by densitometric quantification of band intensities, as compared to its expression in *E. faecalis* JH2-2 ([Supplementary Figures S8B,C](#SM3){ref-type="supplementary-material"}).

SEM analysis showed a statistically significant (*p* \< 0.05) increase in cell length (1.37 ± 0.21 μm, *n* = 202; [Figures 7B,C](#F7){ref-type="fig"}) in *E. faecalis* MK23 as compared to wild type *E. faecalis* JH2-2 cells (1.16 ± 14 μm, *n* = 141; [Figures 7A,C](#F7){ref-type="fig"}).

![EF1025 overexpression in *E. faecalis* JH2-2 cells causes cell elongation. Scanning electron micrographs showing **(A)** *E. faecalis* JH2-2 lancet-shaped cells; **(B)** *E. faecalis* MK23 cells harboring pMSPEF1025A, showing elongated cell morphology. 3 μm bar scale at the bottom right corner of each image establishes the comparison in cell length for *E. faecalis* JH2-2 and MK23; and **(C)** Comparison of cell lengths of *E. faecalis* strains: JH2-2 (*n* = 141), MK23 (*n* = 202) and MK24 (*n* = 226) where "n" represents a number of cells counted for each sample; two-tail *p*-value from *t*-test for each group set has been indicated in the graph. All data was introduced to *t*-test and ANOVA analysis with a *p*-value \< 0.05. The error bars represent 1 standard deviation.](fmicb-11-00083-g007){#F7}

Seventy per cent of cells (63/89) overexpressing *EF1025* in *E. coli* PB103 (i.e. *E. coli* MK23) were filamentous ([Supplementary Figure S9B](#SM3){ref-type="supplementary-material"}) as compared to none of the control cells, i.e. *E. coli* cells with pUC18 and cells overexpressing *prgX~Ef~*, a transcriptional regulator encoding gene ([Supplementary Figures S9A,C](#SM3){ref-type="supplementary-material"}) ([@B15]; [@B3]) in the same vector.

EF1025 Localizes at the Septum and Cell Poles in *E. faecalis* {#S3.SS6}
--------------------------------------------------------------

Immunofluorescence studies of *E. faecalis* JH2-2 cells, using anti-DivIVA~Ef~ or anti-EF1025 polyclonal antibody, determined the localization patterns of DivIVA~Ef~ and EF1025 during cell division. Cell division entailed 5 stages (273 cells counted for DivIVA~Ef~ and 281 for EF1025 localization). During Stage 1, as the cell started to divide and the chromosome started to segregate, DivIVAEf (20.5%, 56/273 cells) localized at the poles and along the length of the cell. In this stage, EF1025 (23.1%, 65/273 cells) was dispersed along the inner membrane ([Figure 8](#F8){ref-type="fig"}, Stage 1). In Stage 2, EF1025 (14.9%, 42/281) localized along the length of the cell in contrast with DivIVA~Ef~ (36.7%, 100/273) that remained localized at the poles and the midcell ([Figure 8](#F8){ref-type="fig"}, Stage 2). At Stage 3, EF1025 (36%, 104/281 cells) and DivIVA~Ef~ (16.1%, 44/273) localized similarly, i.e. to the cell poles and midcell. In Stage 4, as the cells progressed toward completion of cell division, EF1025 (13.2%, 37/281) and DivIVA~Ef~ (16.8%, 46/273) localized as disks and bands along the cell length and septum. With one completed round of cell division (i.e. Stage 5), EF1025 (11.7%, 33/281 cells) was redistributed along the inner membrane before another round of cell division, while DivIVA~Ef~ (9.9%, 27/73) once again localized as dots at the cell poles of the newly formed daughter cells ([Figure 8](#F8){ref-type="fig"}, Stage 5), like Stage 1 cells. The coiled-coil region of DivIVA~Ef~ facilitates oligomerization and is essential for its biological functioning ([@B65]). *E. faecalis* MWMR16 which contains point mutations in the coiled-coil region of DivIVA~Ef~ ([@B65]) exhibited loss of DivIVA~Ef~ localization at the cell poles and midcell position ([Supplementary Figure S10](#SM3){ref-type="supplementary-material"}). The signal was observed to be dispersed all along the membrane and distinct stages of cell division were absent.

![DivIVA~Ef~ and EF1025 localizes similarly in the later stages of cell division in *E. faecalis* JH2-2 cells. Averaged images and fluorescence intensity traces of *E. faecalis* JH2-2 cells grown to mid-exponential phase in BHI broth and dual-stained with DAPI and Alexa-Fluor 488 as described in the methodology section. Cells were segregated into five division Stages, and images from the indicated number of cells (n) were acquired using the *InVitro* 3 and ImagePro 6.0 softwares (Media Cybernetics) as described in Methodology. EF1025 localized at the cell poles and the septa in *E. faecalis* JH2-2 cells similar to DivIVA~Ef~ localization. Column 1 and 4, nucleoid localization from DAPI labeling; Column 2 and 5, DivIVA and EF1025 localization, respectively, in immunofluorescence microscopy; Column 3 and 6, merged image of DAPI stained nucleoid and fluorescent DivIVA~Ef~ and EF1025, respectively.](fmicb-11-00083-g008){#F8}

Discussion {#S4}
==========

In the present study, we investigated a novel DivIVA~Ef~ interacting protein, EF1025, from *E. faecalis*. EF1025 belongs to the CBS pair superfamily and is conserved in Firmicutes including *Bacillus, Streptococcus, Clostridium, Paenibacillus, Staphylococcus, Lactobacillus, Streptomyces* and *Listeria*. Surprisingly, EF1025 homologs in the Firmicutes *S. pneumoniae, S. pyogenes and L. lactis* did not belong to the CBS pair superfamily as they contained an N-terminal HTH domain, but no CBS domains and their sequence similarities ranged from 40 to 44%. We also determined that EF1025 homologs, with uncharacterized functions and different combinations of CBS and HTH domains, may be present in species of the *Proteobacteria* and *Euryarcheota* such as *Vibrio, Campylobacter, Burkholderia, Acinetobacter, Fusobacterium, Methanosarcina*, and *Methanoculleus*. Proteins containing CBS domains are present in organisms ranging from archaea to humans and were originally identified in *Methanococcus jannaschii* as sequence motifs of approximately 60 amino acids ([@B4]). Although several crystallographic studies have been carried out on CBS domains from bacteria, their precise function remains unexplained ([@B5]). It has been postulated that CBS domains may act as allosteric "internal inhibitors" of the functional domains of proteins ([@B1]; [@B7]). Proteins with CBS domains can form dimers through interaction of these domains. For example, TM0935 of *Thermotoga maritima* self-interacts through its two CBS domains forming a dimer ([@B50]). An Mg^2+^ transporter from *E. faecalis*, MgtE, also contains two CBS domains but the precise function of these domains remains unelucidated ([@B62]). Our experiments show the importance of the two CBS domains in EF1025 self-interaction. The absence of one CBS domain resulted in the loss of EF1025 self-interaction.

DivIVA, a topological factor in Gram-positive bacteria, interacts with a variety of proteins in various bacteria ([@B52]; [@B31]). The range of DivIVA interacting partners changes from one genus to another ([@B40]). In *Listeria monocytogenes* (Lm), DivIVA~Lm~, performs a variety of functions through its interaction with different proteins (i.e. MinCD and SecA2), including precise positioning of the septum at midcell, assistance in the secretion of autolysins, and enabling swarming motility ([@B41], [@B42]). In *Streptococcus suis* (Ss) serotype 2, Ser/Thr kinases (STK) directly phosphorylate DivIVA~Ss~ thereby affecting cell growth and division ([@B56]). DivIVA from *S. aureus* (Sa) associates with various divisome proteins (FtsZ~Sa~, FtsA~Sa~, EzrA~Sa~, DivIC~Sa~, DivIB~Sa~, PBP1~Sa~ and PBP2~Sa~) to ensure cell division and chromosome segregation ([@B8]). The molecular chaperone, DnaK, interacts and stabilizes DivIVA~Sa~ in *S. aureus* ([@B11]; [@B8]). [@B8] also reported an indirect function of DivIVA~Sa~ in chromosomal segregation by its interaction with the chromosome segregation protein, SMC ([@B8]). In *Mycobacterium smegmatis* (Ms) and *M. tuberculosis* (Mt), the DivIVA homolog is Wag31 ([@B55]; [@B38]; [@B48]). Wag31~Mt~ interacts with the penicillin-binding protein, PBP3 ([@B53]) as well as ParB ([@B21]) and Wag31~Ms~ interacts with ParA ([@B21]; [@B28]). DivIVA from *E. faecalis* is essential for cell viability and growth, proper cell division and chromosome segregation ([@B63]). [@B65] showed that the oligomerization of DivIVA~Ef~ is mediated by two centrally located coiled coils that are important for its proper biological functioning ([@B65]). *E. faecalis* DivIVA~Ef~ mutant, *E. faecalis* MWMR16, contains a disrupted coiled coil region and failed to interact with EF1025 in a B2H assay due to the loss of a functional coiled-coil region in DivIVA~Ef~ ([@B65]; [@B33]). Our research addressed the essentiality, localization and function of EF1025 during cell division.

Immunostaining showed that EF1025 localized in a pattern comparable to DivIVA~Ef~ in *E. faecalis*. Previously, [@B26] showed DivIVA localization to the mid-cell septa and poles in *S. pneumoniae* using similar methods ([@B26]). EF1025 localized laterally along the cell length in Stages 1 and 2 and a pattern comparable to DivIVA~Ef~ in Stages 3, 4, and 5 of cell division. This localization progression may assist proper cell segregation required for cell division during the later stages of cell division when these two proteins interact. GpsB, an essential protein which determines the ellipsoidal shape in *S. pneumoniae*, localized in a similar but not identical manner to FtsZ, and is implicated in determining cell shape by septal ring closure ([@B43]). There is a possibility that the localization of EF1025 (a cytosolic protein) to the lateral cell regions could be facilitated by DivIVA~Ef~ association. Different domains of DivIVA~Bs~ have been reported to interact with different partners that are membrane proteins as well as cytosolic proteins ([@B59]; [@B9]; [@B57]; [@B10]; [@B22]; [@B2]; [@B30]; [@B66]; [@B31]). Membrane localization of cytosolic proteins enhances the interaction abilities of interacting partners during processes such as cell division which involves multi-protein complex formation ([@B75]).

We postulate that *EF1025* may be an essential gene since, during our attempts to delete or insertionally inactivate the gene, we were never able to recover viable cells. When these strains were complemented with EF1025 (i.e. *E. faecalis* MJ26 and MK12) they grew more slowly, with a longer log phase as compared to the *E. faecalis* JH2-2. The most likely explanation is that the rescue plasmids (i.e. pMSPEF1025-pro and pMSPEF1025A) failed to provide full complementation, which also led to altered cell shape and length. In *S. pneumoniae*, depletion of GpsB, caused cessation of growth and substantial cell elongation ([@B14]; [@B43]). Based on the localization pattern of EF1025 and the elongated and aberrant phenotypes exhibited by *E. faecalis* MK12 cells, and the similarity of their localization patterns, we postulate that EF1025 could be one of the members of the septal machinery in *E. faecalis*, which has an unstudied GpsB homolog.

An interesting EF1025 homolog (41% identity) in *B. subtilis*, named CcpN (control catabolite protein of gluconeogenic genes), has two CBS domains and an HTH domain ([@B67]). CcpN plays a negative regulatory role in the transcription of the gluconeogenic genes *gapB* (one of the GAPDH-encoding genes) and *pckA* (encodes PEP carboxykinase), which are required in carbon catabolite repression pathways ([@B46]; [@B67]; [@B72]; [@B45]). Transcription regulation by CcpN has been attributed to its HTH domain which binds to the conserved upstream promoter regions of *gapB* and *pckA* ([@B46]; [@B67]; [@B72]; [@B45]). We detected strong interactions between CcpN and DivIVA~Bs~ by B2H and GST-pull down assay (paper in preparation). We observed that *gapB* from *B. subtilis* shared 48% homology with *type I gap* from *E. faecalis* while *pckA* from *B. subtilis* and *E. faecalis* showed 20% homology. *E. faecalis* was observed to have *type I* and *type II gap* as two homologs of *gapB*. Our preliminary sequence searches indicate that the conserved upstream promoter sequences from *B. subtilis* are absent in *E. faecalis* for *type I gapB* and *pckA* (unpublished data). This suggests that even though CcpN and EF1025 belong to the same superfamily, they possibly regulate the expression of different genes. CcpN is not an essential gene in contrast to EF1025 ([@B67]; [@B72]), which may result from each protein regulating different genes.

In conclusion, this research presents the first evidence of a DivIVA~Ef~ interacting protein, EF1025, in *E. faecalis* that affects cell viability, cell length and shape. Using immunofluorescence, we showed that the localization patterns of EF1025 and DivIVA~Ef~ during the later stages of cell division in *E. faecalis* were similar. Our inability to insertionally inactivate or delete *EF1025* without in *trans* complementation of the gene indicates that gene is important for viability. Different microscopy methods showed cell elongation, aggregation and impaired cell division in complemented cells with a deleted or inactivated chromosomal gene.
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